Ginkgo Bioworks Holdings (DNA) Research & Development (2020 - 2026)
Ginkgo Bioworks Holdings posted quarterly Research & Development of $49.9 million for Q1 2026, down 29.61% year-on-year from $70.9 million in Q1 2025, and little changed on a QoQ basis from $50.1 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) has 7 years of Research & Development data on file, last reported at $49.9 million in Q1 2026.
- For the quarter ending Q1 2026, Research & Development fell 29.61% year-over-year to $49.9 million; the trailing twelve-month figure through Mar 2026 stood at $222.8 million (down 37.87% YoY), and the FY2025 full-year result was $243.8 million, down 42.51% from the prior year.
- Research & Development for Q1 2026 stood at $49.9 million, roughly flat from $50.1 million in the prior quarter.
- Across five years, Research & Development topped out at $323.6 million in Q1 2022 and bottomed at $49.9 million in Q1 2026.
- The 5-year median for Research & Development is $134.2 million (2024), against an average of $138.3 million.
- Peak annual rise in Research & Development reached 457.47% in 2022, while the deepest fall reached 81.98% in 2022.
- A 5-year view of Research & Development shows it stood at $177.5 million in 2022, then tumbled by 34.08% to $117.0 million in 2023, then sank by 34.74% to $76.4 million in 2024, then slumped by 34.37% to $50.1 million in 2025, then declined by 0.41% to $49.9 million in 2026.
- The last three Research & Development figures came in at $49.9 million (Q1 2026), $50.1 million (Q4 2025), and $69.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Ginkgo Bioworks Holdings | 542.03 Mn | 542.03 Mn | 16.38 Mn | 49.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 49.92 Mn |
| Dec 31, 2025 | 50.13 Mn |
| Sep 30, 2025 | 69.35 Mn |
| Jun 30, 2025 | 53.37 Mn |
| Mar 31, 2025 | 70.92 Mn |
| Dec 31, 2024 | 76.38 Mn |
| Sep 30, 2024 | 77.01 Mn |
| Jun 30, 2024 | 134.22 Mn |
| Mar 31, 2024 | 136.46 Mn |
| Dec 31, 2023 | 117.04 Mn |
| Sep 30, 2023 | 156.66 Mn |
| Jun 30, 2023 | 144.28 Mn |
| Mar 31, 2023 | 162.64 Mn |
| Dec 31, 2022 | 177.55 Mn |
| Sep 30, 2022 | 261.46 Mn |
| Jun 30, 2022 | 290.06 Mn |
| Mar 31, 2022 | 323.58 Mn |
| Dec 31, 2021 | 985.03 Mn |
| Sep 30, 2021 | 53.02 Mn |
| Jun 30, 2021 | 52.03 Mn |
| Mar 31, 2021 | 59.59 Mn |
| Dec 31, 2020 | 61.19 Mn |
| Sep 30, 2020 | 36.07 Mn |